Common Contracts
5 similar Stock Option Agreement contracts by Neumora Therapeutics, Inc., Biomea Fusion, Inc., Sana Biotechnology, Inc.
BLACKTHORN THERAPEUTICS, INC. STOCK OPTION GRANT NOTICE AND STOCK OPTION AGREEMENTStock Option Agreement • September 20th, 2023 • Neumora Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
Blackthorn Therapeutics, Inc. (the “Company”), pursuant to its 2015 Equity Incentive Plan (the “Plan”), hereby grants to the participant set forth below (“Participant”), an option (the “Option”) to purchase the number of shares of the Company’s Common Stock (referred to herein as “Shares”) set forth below. This Option is subject to all of the terms and conditions as set forth herein and in the Stock Option Agreement attached hereto as Exhibit A (the “Stock Option Agreement”) and the Plan, each of which is incorporated herein by reference. Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in this Stock Option Grant Notice and the Stock Option Agreement.
RBNC THERAPEUTICS, INC. STOCK OPTION AGREEMENTStock Option Agreement • August 25th, 2023 • Neumora Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
Pursuant to the option grant summary tab (“Grant Notice”) on the website to which this Stock Option Agreement (this “Agreement”) is associated, RBNC Therapeutics, Inc. (the “Company”) has granted to the option holder set forth in the Grant Notice (“Participant”) an option (the “Option”) under the Company’s 2020 Equity Incentive Plan (the “Plan”) to purchase the number of shares (the “Shares”) indicated in the Grant Notice. By his or her electronic acceptance of this Option on the Grant Notice, Participant agrees to be bound by the terms and conditions of the Plan, this Agreement and the Grant Notice. Participant has reviewed this Agreement, the Plan and the Grant Notice in their entirety, has had an opportunity to obtain the advice of counsel prior to accepting the Option and fully understands all provisions of the Grant Notice, this Agreement and the Plan. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator of the
RBNC THERAPEUTICS, INC. STOCK OPTION AGREEMENTStock Option Agreement • June 30th, 2023 • Neumora Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
Pursuant to the option grant summary tab (“Grant Notice”) on the website to which this Stock Option Agreement (this “Agreement”) is associated, RBNC Therapeutics, Inc. (the “Company”) has granted to the option holder set forth in the Grant Notice (“Participant”) an option (the “Option”) under the Company’s 2020 Equity Incentive Plan (the “Plan”) to purchase the number of shares (the “Shares”) indicated in the Grant Notice. By his or her electronic acceptance of this Option on the Grant Notice, Participant agrees to be bound by the terms and conditions of the Plan, this Agreement and the Grant Notice. Participant has reviewed this Agreement, the Plan and the Grant Notice in their entirety, has had an opportunity to obtain the advice of counsel prior to accepting the Option and fully understands all provisions of the Grant Notice, this Agreement and the Plan. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator of the
BIOMEA FUSION, INC. STOCK OPTION AGREEMENTStock Option Agreement • March 26th, 2021 • Biomea Fusion, Inc. • Pharmaceutical preparations • Delaware
Pursuant to the option grant summary tab (“Grant Notice”) on the website to which this Stock Option Agreement (this “Agreement”) is associated, Biomea Fusion, Inc. (the “Company”) has granted to the option holder set forth in the Grant Notice (“Participant”) an option (the “Option”) under the Company’s 2020 Equity Incentive Plan (the “Plan”) to purchase the number of shares of Common Stock (the “Shares”) indicated in the Grant Notice. By his or her electronic acceptance of this Option on the Grant Notice, Participant agrees to be bound by the terms and conditions of the Plan, this Agreement and the Grant Notice. Participant has reviewed this Agreement, the Plan and the Grant Notice in their entirety, has had an opportunity to obtain the advice of counsel prior to accepting the Option and fully understands all provisions of the Grant Notice, this Agreement and the Plan. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administr
SANA BIOTECHNOLOGY, INC. STOCK OPTION GRANT NOTICE AND STOCK OPTION AGREEMENTStock Option Agreement • January 13th, 2021 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances) • Delaware
Sana Biotechnology, Inc. (the “Company”), pursuant to its 2018 Equity Incentive Plan (the “Plan”), hereby grants to the participant set forth below (“Participant”), an option (the “Option”) to purchase the number of shares of the Company’s Common Stock (referred to herein as “Shares”) set forth below. This Option is subject to all of the terms and conditions as set forth herein and in the Stock Option Agreement attached hereto as Exhibit A (the “Stock Option Agreement”) and the Plan, each of which is incorporated herein by reference. Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in this Stock Option Grant Notice and the Stock Option Agreement.
